TREM2 and neoplasm: In the anti-PD-1 resistant colon carcinoma model CT26, the combination of anti-TREM2 and anti-PD-1 elicited tumor rejection in 20–60% of treated mice, along with increased infiltration of activated CD8 T cells [74].